Cyclacel Pharmaceuticals CEO Spiro Rombotis' 2023 pay slips 13% to $661K
Cyclacel Pharmaceuticals reports 2023 executive compensation
By ExecPay News
Published: May 7, 2024
Cyclacel Pharmaceuticals reported fiscal year 2023 executive compensation information on May 7, 2024.
In 2023, three executives at Cyclacel Pharmaceuticals received on average a compensation package of $498K, a 11% decrease compared to previous year.
Average pay of disclosed executives at Cyclacel Pharmaceuticals
Spiro Rombotis, Chief Executive Officer, received $661K in total, which decreased by 13% compared to 2022. 85% of Rombotis' compensation, or $560K, was in salary. Rombotis also received $49K in option awards and $52K in other compensation.
Mark Kirschbaum, Chief Medical Officer, received a compensation package of $481K, which decreased by 8% compared to previous year. 83% of the compensation package, or $397K, was in salary.
Paul McBarron, Chief Financial Officer, earned $353K in 2023, a 11% decrease compared to previous year.
Related executives
You may also like
Source: SEC filing on May 7, 2024.